{"id":"W3081315565","doi":"10.1016/s1470-2045(20)30447-2","title":"Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":321,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; AstraZeneca; Invitae; PharmaMar; Eisai; Pfizer","keywords":"Veliparib; Carboplatin; Oncology; Medicine; Placebo; Breast cancer; Internal medicine; BRCA mutation; Paclitaxel; Cancer; Chemotherapy; Biology; Genetics; Alternative medicine; Poly ADP ribose polymerase; Cisplatin; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001654523,0.001973495,0.003197133,0.0004399658,0.0005126193,0.001487806,0.001183789,0.002311567,0.009383349],"category_scores_gemma":[0.001597789,0.0007900677,0.002528108,0.0005803425,0.001258778,0.001227451,0.0004817037,0.004314199,0.00168195],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001013354,"about_ca_system_score_gemma":0.001100402,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0016588,"about_ca_topic_score_gemma":0.003452639,"domain_scores_codex":[0.9994254,0.0002608319,0.00002871211,0.0001251497,0.00004056028,0.0001193836],"domain_scores_gemma":[0.9993842,0.0001803266,0.000136848,0.00005780456,0.00003493245,0.0002059438],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.985104,0.002000474,0.0001565642,0.0006134007,0.0008735593,0.00002817953,0.00003022802,0.0002539576,0.001358237,0.0001199682,0.001024986,0.008436336],"study_design_scores_gemma":[0.9863434,0.01219937,0.0004156991,0.00002398353,0.0002141591,0.00001863094,0.000009815364,0.0001362126,0.0001074296,0.0001067957,0.0004154175,0.000009117639],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9618255,0.01512365,0.001494193,0.002056065,0.001490241,0.007901863,0.003863776,0.0004745638,0.005770176],"genre_scores_gemma":[0.969234,0.007888721,0.002134555,0.002749688,0.0006033727,0.007032774,0.002678137,0.00008196157,0.007596899],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009383349,"threshold_uncertainty_score":0.03139043,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07829391178294297,"score_gpt":0.3971052690556947,"score_spread":0.3188113572727517,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}